focetria
novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/california/7/2009 (h1n1)-derived strain used nymc x-181 - influenza, human; immunization; disease outbreaks - influenza vaccines - prophylaxis of influenza caused by a (h1n1v) 2009 virus.focetria should be used in accordance with official guidance.
fluad, suspension for injection in pre-filled syri 0.5 suspension for injection
novartis vaccines and diagnostics s.r.l. - a/california/7/2009 (h1n1)pdm09-derived strain used (nymc x-181) a/texas/50/2012 (h3n2) derived strain used (nymc x-233a) b/massachusetts/2/2012-like strain used b/massachusetts/2/2012 wild type - suspension for injection - 0.5
inflexal v 15 microgram suspension for injection
crucell italy s.r.l. - a/california/7/2009 (h1n1)pdm09-derived strain used (nymc x-181) a/victoria/361/2011 (h3n2)-like strain used (nymc x-223a) derived from a/texas/50/2012 b/massachusetts/02/2012 derived strain used (nymc bx-51b) - suspension for injection - 15 microgram
agrippal suspension for injection
novartis vaccines and diagnostics s.r.l. - a/california/7/2009 (h1n1)pdm09-derived strain used (nymc x-181) a/texas/50/2012 (h3n2) derived strain used (nymc x-233a) b/massachusetts/2/2012-like strain used b/massachusetts/2/2012 wild type - suspension for injection
prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics
novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain a/viet nam/1194/2004 (h5n1) - influenza, human - vaccines - active immunisation against h5n1 subtype of influenza a virus.; this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain.; prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.
prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics
novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain a/viet nam/1194/2004 (h5n1) - influenza, human, immunization, disease outbreaks - vaccines, - active immunisation against h5n1 subtype of influenza a virus., this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain., prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.,
pandemrix
glaxosmithkline biologicals s.a. - split influenza virus inactivated, containing antigen equivalent to a/california/07/2009 (h1n1)-derived strain used nymc x-179a - influenza, human; immunization; disease outbreaks - influenza vaccines - prophylaxis of influenza caused by a (h1n1)v 2009 virus. pandemrix should only be used if the recommended annual seasonal trivalent / quadrivalent influenza vaccines are not available and if immunisation against (h1n1)v is considered necessary (see sections 4.4 and 4.8).pandemrix should be used in accordance with official guidance.
zoonotic influenza vaccine seqirus
seqirus s.r.l. - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - vaccines - active immunisation against h5 subtype of influenza a virus
aflunov
seqirus s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza, human; immunization; disease outbreaks - vaccines - active immunisation against h5n1 subtype of influenza-a virus.this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/turkey/turkey/1/05 (h5n1)-like strain.aflunov should be used in accordance with official recommendations.
aflunov suspension for injection 0.5ml in pre-filled syringe
seqirus pte. ltd. - influenza virus surface antigens (haemagglutinin and neuraminidase) a/turkey/turkey/1/05 (h5n1)-like strain used (nibrg-23) - injection, suspension - > or = 7.5 ug ha - influenza virus surface antigens (haemagglutinin and neuraminidase) a/turkey/turkey/1/05 (h5n1)-like strain used (nibrg-23) 7.5 ug ha/0.5 ml